When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...

CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) and Johns Hopkins University have successfully submitted our proposal for a NIH Grant that will utilize CTT's patented technology as a smoking cessation ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...